Journal
FRONTIERS IN MICROBIOLOGY
Volume 13, Issue -, Pages -Publisher
FRONTIERS MEDIA SA
DOI: 10.3389/fmicb.2022.835677
Keywords
antibody; antibiotic; antibody-antibiotic conjugates; bacteria; infections; resistance
Categories
Ask authors/readers for more resources
The emergence of antimicrobial resistance poses a significant healthcare challenge in the twenty-first century. Antibody-antibiotic conjugates (AACs) provide an alternative to conventional antibiotics, utilizing the selectivity and safety of antibodies to deliver more potent antibiotics with fewer off-target effects. Despite the complexity of developing AACs, some successful examples are currently undergoing clinical studies.
The emergence of antimicrobial resistance (AMR) is rapidly increasing and it is one of the significant twenty-first century's healthcare challenges. Unfortunately, the development of effective antimicrobial agents is a much slower and complex process compared to the spread of AMR. Consequently, the current options in the treatment of AMR are limited. One of the main alternatives to conventional antibiotics is the use of antibody-antibiotic conjugates (AACs). These innovative bioengineered agents take advantage of the selectivity, favorable pharmacokinetic (PK), and safety of antibodies, allowing the administration of more potent antibiotics with less off-target effects. Although AACs' development is challenging due to the complexity of the three components, namely, the antibody, the antibiotic, and the linker, some successful examples are currently under clinical studies.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available